PURE Bioscience, Inc. PURE
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.50% | 21.89% | 30.29% | 34.20% | 28.39% |
| Total Depreciation and Amortization | 50.00% | -95.00% | -96.00% | -97.30% | -98.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.01% | 14.19% | -27.57% | -50.60% | -46.35% |
| Change in Net Operating Assets | 131.91% | -48.32% | -67.81% | -18.10% | -40.81% |
| Cash from Operations | 13.75% | 17.29% | 19.11% | 32.07% | 20.39% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -51.50% | -45.78% | -4.21% | 23.33% | 12.04% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.35% | -1.20% | -4.21% | 23.33% | 12.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,666.67% | 352.04% | 98.87% | 108.04% | 97.99% |